Insulet (NASDAQ:PODD) Price Target Raised to $385.00 at Raymond James Financial

Insulet (NASDAQ:PODD) had its price target raised by Raymond James Financial from $366.00 to $385.00 in a report issued on Friday,MarketScreener reports. The brokerage currently has an outperform rating on the medical instruments supplier’s stock.

PODD has been the subject of a number of other research reports. Piper Sandler raised their price objective on shares of Insulet from $320.00 to $360.00 and gave the company an “overweight” rating in a report on Tuesday, September 16th. Stifel Nicolaus started coverage on shares of Insulet in a research report on Tuesday, October 21st. They issued a “buy” rating and a $370.00 price target for the company. Wall Street Zen upgraded shares of Insulet from a “hold” rating to a “buy” rating in a report on Saturday, August 9th. Barclays boosted their price objective on shares of Insulet from $300.00 to $301.00 and gave the stock an “equal weight” rating in a research note on Wednesday, November 5th. Finally, UBS Group raised Insulet from a “neutral” rating to a “buy” rating and raised their target price for the stock from $355.00 to $400.00 in a research report on Wednesday. One analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat, Insulet presently has a consensus rating of “Moderate Buy” and a consensus price target of $379.45.

Insulet Price Performance

PODD traded up $18.28 during trading on Friday, hitting $331.17. 1,416,564 shares of the stock traded hands, compared to its average volume of 724,556. Insulet has a twelve month low of $230.05 and a twelve month high of $354.88. The company has a market cap of $23.30 billion, a price-to-earnings ratio of 100.66, a PEG ratio of 2.64 and a beta of 1.39. The company has a debt-to-equity ratio of 0.64, a current ratio of 2.26 and a quick ratio of 1.81. The business has a 50 day moving average price of $322.22 and a 200 day moving average price of $314.69.

Insulet (NASDAQ:PODD) last posted its quarterly earnings results on Thursday, November 6th. The medical instruments supplier reported $1.24 earnings per share for the quarter, beating analysts’ consensus estimates of $1.13 by $0.11. Insulet had a net margin of 10.01% and a return on equity of 23.78%. The company had revenue of $521.70 million for the quarter, compared to the consensus estimate of $678.70 million. During the same period last year, the company posted $1.08 EPS. The firm’s quarterly revenue was up 29.9% compared to the same quarter last year. Insulet has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. Equities research analysts forecast that Insulet will post 3.92 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, SVP Laetitia Cousin sold 797 shares of the business’s stock in a transaction on Monday, September 8th. The shares were sold at an average price of $348.81, for a total value of $278,001.57. Following the transaction, the senior vice president owned 3,890 shares in the company, valued at $1,356,870.90. The trade was a 17.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Prem Singh sold 687 shares of the stock in a transaction dated Monday, September 8th. The stock was sold at an average price of $347.49, for a total value of $238,725.63. Following the sale, the senior vice president owned 3,456 shares of the company’s stock, valued at approximately $1,200,925.44. The trade was a 16.58% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 0.39% of the stock is owned by company insiders.

Institutional Trading of Insulet

Several hedge funds have recently modified their holdings of PODD. Inspire Investing LLC boosted its holdings in shares of Insulet by 299.5% in the first quarter. Inspire Investing LLC now owns 4,119 shares of the medical instruments supplier’s stock worth $1,082,000 after acquiring an additional 3,088 shares during the period. Marshall Financial Group LLC purchased a new stake in Insulet during the 2nd quarter worth about $943,000. Illinois Municipal Retirement Fund lifted its holdings in Insulet by 41.3% during the 2nd quarter. Illinois Municipal Retirement Fund now owns 12,030 shares of the medical instruments supplier’s stock worth $3,780,000 after purchasing an additional 3,514 shares in the last quarter. Gradient Investments LLC bought a new position in Insulet in the 2nd quarter worth about $17,429,000. Finally, Goldman Sachs Group Inc. grew its holdings in Insulet by 1.9% during the 1st quarter. Goldman Sachs Group Inc. now owns 579,302 shares of the medical instruments supplier’s stock valued at $152,130,000 after buying an additional 10,628 shares in the last quarter.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.